Charts

~ Webcast Replay Available on Ensysce's Investor Relations Website ~

SAN DIEGO, CA / ACCESSWIRE / April 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse and overdose, today announced its participation in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, and Dave Humphrey, Chief Financial Officer of Ensysce, are scheduled to present on Wednesday, April 17th at 2:00 PM Eastern Time. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fisker stock is on the move Monday as FSR investors learn about the EV company securing an additional $150 million in funding. The post FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ENSC stock results show that Ensysce Biosciences missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. The post ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) released its 2023 annual report and reiterated the positive results seen throughout the year that we have previously reported on. Some highlights: • Cash ended the year at $1.1 million but since, as we’ve noted, the company has added $2.1 million from the exercise of warrants and, in a separate

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical Plans

SAN DIEGO, CA / ACCESSWIRE / February 27, 2024 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq"), as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to May 13, 2024 in order to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1).

~ PF614-MPAR program receives FDA guidance ~ SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription ...

~ PF614-MPAR program receives FDA guidance ~

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) announced that it has published a manuscript in the peer-reviewed medical journal Clinical and Translational Science. The manuscript highlighted its PF614 drug, and the testing done that compared it to OxyContin. The tests showed that PF614, which is abuse resistant as we’ve described in detail

Publication Details Positive Results of Clinical Study PF614-102 SAN DIEGO, CA / ACCESSWIRE / February 15, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)(OTC PINK:ENSCW) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry ...

Publication Details Positive Results of Clinical Study PF614-102

Gainers KalVista Pharma (NASDAQ:KALV) stock moved upwards by 31.5% to $21.1 during Tuesday's pre-market session. The market value of ...

SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,601,752 shares of common stock of the Company originally issued in May 2023, having an exercise price of $3.637 per share, at a reduced exercise price of $1.31 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-271480). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.7 million, prior to deducting placement agent fees and estimated offering expenses.

~ PF614-MPAR recognized as potential medical breakthrough ~

Gainers TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 17.2% to $0.81 during Wednesday's after-market session. Align ...

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported ...

~ PF614 Phase 3 Program Expected to Begin Enrollment in Mid-2024 ~ SAN DIEGO, CA / ACCESSWIRE / January 31, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to ...

~ PF614 Phase 3 Program Expected to Begin Enrollment in Mid-2024 ~

SAN DIEGO, CA / ACCESSWIRE / January 25, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Geoff Birkett, Chief Commercial Officer of Ensysce, will present a poster entitled "PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP™) Extended-Release Oxycodone Prodrug with Overdose Protection" at the Annual National Institutes of Health (NIH) "Helping to End Addiction Long-term" (HEAL) Initiative Scientific Meeting being held on February 7 and 8, 2024, in Bethesda, MD.

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private ...

Gainers Kura Oncology (NASDAQ:KURA) stock rose 48.1% to $19.87 during Wednesday's regular session. The market value of their ...

Shares of Netflix, Inc. (NASDAQ: NFLX) shares rose sharply in today’s pre-market trading as the company reported ...

Gainers Redhill Biopharma (NASDAQ:RDHL) shares rose 11.1% to $0.99 during Tuesday's after-market session. The market value of their ...

U.S. stocks traded mixed toward the end trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down ...

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected ...

Ensysce Biosciences Inc(NASDAQ:ENSC)receivedan FDA Breakthrough Therapy Designation (BTD) for PF614-MPAR, a ...

Gainers Ensysce Biosciences (NASDAQ:ENSC) shares moved upwards by 46.5% to $1.67 during Tuesday's regular session. The market value of ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded down ...

~ FDA acknowledges significant potential impact of MPAR's oral overdose protection ~ SAN DIEGO, CA / ACCESSWIRE / January 23, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative ...

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) announced that its next generation opioid, PF614-MPAR, has been granted Breakthrough Therapy Designation (BTD) by the FDA. This designation is extremely valuable and has been granted to fewer than 300 drugs, according to the FDA and punctuates our continued belief that PF614-MPAR has the chance

~ FDA acknowledges significant potential impact of MPAR's oral overdose protection ~

Gainers Jin Medical International (NASDAQ:ZJYL) shares moved upwards by 19.2% to $93.0 during Monday's pre-market session. The ...

SAN DIEGO, CA / ACCESSWIRE / January 8, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick.

Gainers NuCana (NASDAQ:NCNA) shares rose 15.6% to $0.35 during Thursday's after-market session. The market value of their outstanding ...

SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced that the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on December 20, 2023 at 9:00 a.m. Pacific Time has been postponed due to lack of the required quorum.

Shares of Getaround, Inc. (NYSE: GETR) rose sharply in pre-market trading after the company reported a year-over-year increase in ...

Results Reinforce Efficacy of PF614 as a Next Generation Analgesic with Significant Pain Intensity ReductionPF614 Clinical Data Primes FDA Evaluation and Design of Phase 3 Studies in 2024

PHOENIX, AZ / ACCESSWIRE / December 11, 2023 / The Stock Day Podcast welcomed Ensysce Biosciences (NASDAQ:ENSC) ("the Company"), a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs.CEO of the Company, Dr. Lynn Kirkpatrick, joined Stock Day host Matthew Dunehoo.

Gainers Exicure (NASDAQ:XCUR) stock increased by 63.9% to $0.66 during Friday's pre-market session. The market value of their ...

Gainers NexImmune (NASDAQ:NEXI) stock moved upwards by 540.4% to $11.07 during Friday's regular session. The market value of their ...

Additional Funding from Investors Validates Company's Mission

Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer Treatment

~ Enrollment Completion Signifies Critical Progress to Phase 3 of PF614 ~

PF614-201 Clinical Study Results Expected by End of Year

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the ...

Additional Funding from Investor Cohort Validates Company's Mission

Gainers SeaStar Medical Holding Corporation (NASDAQ: ICU) shares climbed 36.4% to $1.0516. SeaStar medical shares jumped 70% on ...

Gainers Nxu, Inc. (NASDAQ: NXU) shares surged 56.4% to $0.1079 in pre-market trading. On Oct. 17, Nxu received formal notice from ...

Poster Presentation to Showcase the Optimization Process of Ensysce's PF614-MPAR Formulation

Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on ...

~ A showcase of PF614 and PF614-MPAR ~

~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~

~ Geoff Birkett, CCO of Ensysce, to Chair Meeting, Deliver Opening Remarks and Present a Case Study on Drug Launch Process ~

~ Study Initiation Brings PF614 One Necessary Step Closer to Phase 3 ~